Rigosertib Explained

Rigosertib (ON-01910 sodium salt, with Estybon as trade name) is a synthetic benzyl styryl sulfone in development by Onconova Therapeutics.[1] Rigosertib is in phase III clinical trials for the treatment of chronic myelomonocytic leukemia.[2]

Its geometrical isomer (Z)-ON 01910·Na has less cytotoxicity on cancer cells.

Mechanism

Rigosertib is a microtubule-destabilizing agent.[3]

Notes and References

  1. Web site: Onconova Therapeutics. 2019-04-26.
  2. Web site: Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients with Myelodysplastic Syndrome with Excess Blasts Progressing on or After Azacitidine or Decitabine. 29 June 2020.
  3. Jost. M. Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent. Molecular Cell. 68 . 1. 210–223.e6. 28985505. 5640507. 2017. 10.1016/j.molcel.2017.09.012.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Rigosertib".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.